Navigation Links
PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
Date:5/2/2013

INCLINE VILLAGE, Nev., May 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2013 financial results for the period ended March 31, 2013, on Thursday, May 9, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Conference Call Details
To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 59911834. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through May 15, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 59911834.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... March 8, 2012 , Quality of Life ... available treatment fails in two thirds of patients ... Pevion Biotech AG today announced results from a large, ... vulvovaginal candidiasis (RVVC) patients. It is the first time that ...
... Inc. (Nasdaq: BIOD ) today announced that ... will present a corporate update at the ROTH 24th Annual ... 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). ... Conference will be held March 11-14, 2012, at the ...
Cached Medicine Technology:Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 2Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 3Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 4
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... show signs of chronic inflammation in non-cancerous prostate tissue ... prostate cancer than those with no inflammation, according to ... the Johns Hopkins Kimmel Cancer Center. , The link ... men with so-called high-grade prostate cancer those with ... the presence of the most aggressive and rapidly growing ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... of DNA testing and genetic profiling is proving many skeptics wrong. ... tests outweigh consumers, privacy concerns. From dating, through genealogy, to ... health and lifestyle decisions is gaining acceptance. , ... ...
... OBESE MAY CARRY ASTHMA TRAIT , A new study ... carry a specific trait or phenotype that causes them ... not obese with asthma. Researchers from Quebec, Canada compared ... counts, symptom perceptions, BMI/waist circumference, and waist-to-hip ratio of ...
... Aug. 4 The Kansas Health Policy,Authority (KHPA) has ... enable the agency to analyze the cost and effectiveness ... of a data repository and a data analytic,interface (DAI) ... several,state programs. Andy Allison, KHPA,s deputy director and Medicaid ...
... HILL In the budding field of nanotechnology, scientists already ... the University of North Carolina at Chapel Hill have shown ... lead to new and more effective methods for treating cancer ... and obesity. , A team of researchers led by Joseph ...
... to start or continue smoking, researchers say , , MONDAY, Aug. ... appears to have a stronger effect in people who smoke, ... heart attack patients after the attack. It inhibits formation of ... 259 people given Plavix because of coronary conditions found that ...
... 2008 Revenue Increases 36% to $16.9 Million ... Sets Quarterly Record ... MINNEAPOLIS, Aug. 4 ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... results for the,second quarter ended June 28, 2008. Revenue for the ...
Cached Medicine News:Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 2Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 3Health News:Chest Journal: August news briefs 2Health News:Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative 2Health News:Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative 3Health News:UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies 2Health News:UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies 3Health News:Blood-Thinner Plavix Works Harder in Smokers 2Health News:ATS Medical Announces Second Quarter Results 2Health News:ATS Medical Announces Second Quarter Results 3Health News:ATS Medical Announces Second Quarter Results 4Health News:ATS Medical Announces Second Quarter Results 5Health News:ATS Medical Announces Second Quarter Results 6Health News:ATS Medical Announces Second Quarter Results 7Health News:ATS Medical Announces Second Quarter Results 8Health News:ATS Medical Announces Second Quarter Results 9Health News:ATS Medical Announces Second Quarter Results 10
... Tosoh Corporation launched the first generation HPLC ... HPLC/723Ghb brought a new level of automation ... forefront of diabetes testing in Japan. Now ... system, the G7 offers advanced automation; stable ...
... , Monoclonal antibody method for HbA1c ... study shows 99% agreement with the HPLC ... on a CV of 2.6%* means ... Standardization Program (NGSP) certified method, as recommended ...
... Maximize your laboratorys ... and enhanced automated workflow ... high-throughput automated workstation now ... and immunoassay with specimen ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: